But it will be up to doctors whether to use the combo in Darzalex-exposed patients.
ApexOnco Front Page
Recent articles
Persevera is a bust, but Roche hasn’t given up on the front line.
After several discontinuations, a new ADC enters the clinic.
TARA-002 goes from looking better than Inlexzo to seeming rather worse.
The company's partner MediLink will start a pivotal trial of beruzatatug pelitecan in lung cancer.
Hutchmed goes pivotal with HMPL-760 in B-cell lymphoma.
Median PFS appears to back earlier response rate promise.
Solstice Oncology acquires porustobart from Harbour Biomed.
